Sonoma Pharmaceuticals (SNOA) Return on Capital Employed (2011 - 2026)

Sonoma Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 27.47% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 1124.0% year-over-year to 27.47% in Q1 2026; TTM through Mar 2026 was 27.47%, a 1124.0% increase from a year earlier, with the FY2026 full-year figure at 27.36%, up 930.0% from the prior year.
• Return on Capital Employed climbed to 27.47% in Q1 2026 per SNOA's latest filing, from 29.05% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 27.47% in Q1 2026 and bottomed at 61.65% in Q4 2022.
• The 5-year median for Return on Capital Employed is 41.23% (2024), against an average of 41.34%.
• Across the five-year window, Return on Capital Employed tumbled 2575 bps in 2022 and soared 2149 bps in 2023, its largest moves.
• Year by year, Return on Capital Employed stood at 61.65% in 2022, then surged by 35 bps to 40.16% in 2023, then retreated by 11 bps to 44.75% in 2024, then jumped by 35 bps to 29.05% in 2025, then increased by 5 bps to 27.47% in 2026.
• Per Business Quant, the three latest SNOA Return on Capital Employed figures stand at 27.47% (Q1 2026), 29.05% (Q4 2025), and 31.5% (Q3 2025).